Next Article in Journal
Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis
Next Article in Special Issue
TIM-3 Expression Is Downregulated on Human NK Cells in Response to Cancer Targets in Synergy with Activation
Previous Article in Journal
Molecular Biology of Osteosarcoma
Previous Article in Special Issue
Genetic and Molecular Basis of Heterogeneous NK Cell Responses against Acute Leukemia
Review

Natural Born Killers: NK Cells in Cancer Therapy

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Cancers 2020, 12(8), 2131; https://doi.org/10.3390/cancers12082131
Received: 6 July 2020 / Revised: 21 July 2020 / Accepted: 27 July 2020 / Published: 31 July 2020
(This article belongs to the Special Issue The Role of NK and T Cells in Cancer)
Cellular therapy has emerged as an attractive option for the treatment of cancer, and adoptive transfer of chimeric antigen receptor (CAR) expressing T cells has gained FDA approval in hematologic malignancy. However, limited efficacy was observed using CAR-T therapy in solid tumors. Natural killer (NK) cells are crucial for tumor surveillance and exhibit potent killing capacity of aberrant cells in an antigen-independent manner. Adoptive transfer of unmodified allogeneic or autologous NK cells has shown limited clinical benefit due to factors including low cell number, low cytotoxicity and failure to migrate to tumor sites. To address these problems, immortalized and autologous NK cells have been genetically engineered to express high affinity receptors (CD16), CARs directed against surface proteins (PD-L1, CD19, Her2, etc.) and endogenous cytokines (IL-2 and IL-15) that are crucial for NK cell survival and cytotoxicity, with positive outcomes reported by several groups both preclinically and clinically. With a multitude of NK cell-based therapies currently in clinic trials, it is likely they will play a crucial role in next-generation cell therapy-based treatment. In this review, we will highlight the recent advances and limitations of allogeneic, autologous and genetically enhanced NK cells used in adoptive cell therapy. View Full-Text
Keywords: natural killer cells; NK cells; adoptive cell transfer; NK-92; CAR-NK; haNK; t-haNK natural killer cells; NK cells; adoptive cell transfer; NK-92; CAR-NK; haNK; t-haNK
Show Figures

Figure 1

MDPI and ACS Style

Franks, S.E.; Wolfson, B.; Hodge, J.W. Natural Born Killers: NK Cells in Cancer Therapy. Cancers 2020, 12, 2131. https://doi.org/10.3390/cancers12082131

AMA Style

Franks SE, Wolfson B, Hodge JW. Natural Born Killers: NK Cells in Cancer Therapy. Cancers. 2020; 12(8):2131. https://doi.org/10.3390/cancers12082131

Chicago/Turabian Style

Franks, S. E., Benjamin Wolfson, and James W. Hodge 2020. "Natural Born Killers: NK Cells in Cancer Therapy" Cancers 12, no. 8: 2131. https://doi.org/10.3390/cancers12082131

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop